Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478971 · ClinicalTrials.gov registry record · Phase 3
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
A Phase 3 study of Chronic Kidney Disease and Anemia, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
- 5
- Study locations
NCT01478971: Completed Phase 3 study of Chronic Kidney Disease and Anemia, sponsored by Takeda.
NCT01478971 is a Phase 3 study of Chronic Kidney Disease and Anemia that has completed, run by Takeda. The registered enrollment target is 184 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01478971, a Phase 3 study of Chronic Kidney Disease and Anemia, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to understand the effects of a dialysis center switching its dialysis patients from using Epoetin alfa to peginesatide injection on hemoglobin levels and other parameters.
Conditions Studied
Interventions
- DRUG Epoetin
- DRUG Peginesatide
Study Locations (5)
California
- Research Facility - Sacramento
- Research Facility - San Diego
- Research Facility - San Jose
New Jersey
- Research Facility - North Brunswick
Texas
- Research Facility - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
What the finished NCT01478971 record still lists
NCT01478971 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Epoetin is the first listed.
NCT01478971 lists 5 locations in 3 states (California, New Jersey, Texas).
Frequently Asked Questions
What is clinical trial NCT01478971 about?
NCT01478971 is a clinical study titled "Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis". The purpose of this study is to understand the effects of a dialysis center switching its dialysis patients from using Epoetin alfa to peginesatide injection on hemoglobin levels and other parameters.
What is the current status of trial NCT01478971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2011-10. Estimated completion is 2013-02.
What conditions does trial NCT01478971 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Anemia.
What interventions are being tested in trial NCT01478971?
The interventions under investigation include: Epoetin (DRUG), Peginesatide (DRUG).
Who is sponsoring clinical trial NCT01478971?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01478971 being conducted?
This trial has 5 study locations across California, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01478971's enrollment target sits among peer trials
184 40th of 101 higher than 62 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia